Elekta stock holds steady as latest earnings and oncology demand support outlook

Elekta stock is trading in a stable range as investors digest the company’s most recent quarterly results, including higher order intake and solid margins driven by demand for radiotherapy and oncology solutions.

Elekta (ISIN SE0000163628) stock is trading in a stable corridor as of August 24, 2026, with investors focusing on the company’s latest quarterly earnings and continued demand for its radiotherapy solutions.

Earnings and orders underpin Elekta’s story

In its most recent reported quarter for fiscal 2026, Elekta posted revenue at a level that reflects solid growth versus the comparable period a year earlier, supported by higher equipment deliveries and service contracts in oncology care.

The same quarter saw order intake increase compared with the prior year’s quarter, signaling that hospitals and cancer centers are continuing to commit capital to Elekta’s treatment systems and software despite budget pressures.

Elekta also reported a positive operating margin in this latest quarter, demonstrating that cost control and mix of higher-margin service revenue are offsetting inflationary pressures and helping the company convert top-line growth into earnings.

Balance sheet, cash flow and guidance context

Alongside the income statement figures, Elekta’s latest quarterly report showed a stable net debt position, with leverage ratios remaining within management’s target range and providing flexibility for continued investment in innovation.

Free cash flow for the same period was positive, aided by improved working-capital management and strong customer collections, which supports Elekta’s ability to fund research and development and maintain its dividend policy.

Management confirmed its guidance framework for the current fiscal year in the most recent communication, including expectations for continued growth in net sales and operating income driven by a robust order backlog and ongoing service revenue.

Product spotlight: radiotherapy platforms

A core element of Elekta’s business model is its portfolio of radiotherapy platforms used in the treatment of cancer, which integrate hardware, software and precision imaging to deliver targeted radiation to tumors while sparing healthy tissue.

These systems are typically sold with long-term service and maintenance contracts, creating recurring revenue streams that complement the initial equipment sale and support Elekta’s margin and cash-flow profile over time.

Stock valuation and trading context

As of August 24, 2026, Elekta’s market capitalization reflects investor expectations that the company will continue to grow earnings through a combination of new system installations, upgrades of existing equipment and expansion of software offerings.

The shares are trading below their recent 52-week highs but remain above the lows reached earlier in the fiscal year, indicating that the market is pricing in both the company’s operational progress and sector-wide uncertainties.

For investors evaluating Elekta stock as of August 24, 2026, the key numerical anchors are the latest quarterly revenue and margin figures, the year-over-year increase in order intake, and the current valuation relative to the company’s earnings power.

Read more

Further details on Elekta’s investor information and financial reporting are available through its dedicated investor relations resources.

Elekta’s oncology offering

Elekta’s oncology solutions encompass radiotherapy systems, treatment-planning software and related services that enable clinicians to design and deliver complex radiation treatments tailored to individual patients.

The company’s installed base across hospitals and cancer centers worldwide provides a platform for ongoing software upgrades and service revenue, making its product portfolio central to both clinical outcomes and the long-term investment case.

Elekta stock and current market view

As of August 24, 2026, Elekta stock trades on its home market exchange, and the latest available quote places the shares in a range that implies a price-earnings multiple aligned with other established medical-technology names.

This price context, together with the most recent quarterly revenue, margin and order trends, frames the way investors assess Elekta stock in the broader healthcare and oncology-equipment sector.

Fact box

Company: Elekta AB

ISIN: SE0000163628

Ticker: EKTAB

Exchange: Nasdaq Stockholm

Sector / Industry: Health care equipment and services

Index membership: Health care sector index